{
  "abstract": "Background: Cardiac amyloid light-chain (AL) amyloidosis carries a poor prognosis and is considered largely irreversible once symptomatic. Long-term serial cardiovascular magnetic resonance (CMR) data following B-cell maturation antigen-directed therapy are lacking.\n\nCase Summary: A 64-year-old man with biopsy-proven cardiac AL amyloidosis achieved sustained hematologic complete response after teclistamab following failure of 4 prior lines including daratumumab. Eleven CMR examinations over 9 years documented a biphasic trajectory: progressive infiltration through 2020 (left ventricular mass 186 g, wall thickness 18 mm, global longitudinal strain −4.8%), followed by sustained structural and functional regression through 2025 (left ventricular mass 127 g, wall thickness 13 mm, global longitudinal strain −13.7%).\n\nDiscussion: This represents the longest serial CMR follow-up in cardiac AL amyloidosis reported to date, demonstrating that cine-derived parameters reliably track cardiac regression in real-world conditions. Native T1 normalized while extracellular volume fraction (ECV) paradoxically increased, suggesting persistent fibril burden beyond hematologic clearance.\n\nTake-Home Message: Serial CMR with cine-derived parameters provides robust longitudinal monitoring of cardiac AL amyloidosis regression following novel plasma cell–directed therapy, even without systematic contrast enhancement.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Radiology and Cardiovascular Imaging, GHICL–Groupement des Hôpitaux de l’Institut Catholique de Lille, Lille, France",
    "Department of Hematology, GHICL–Groupement des Hôpitaux de l'Institut Catholique de Lille–Hôpital Saint-Vincent-de-Paul, Lille, France"
  ],
  "article_type": "case report",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Valentina Silvestri"
    },
    {
      "affs": [
        0
      ],
      "name": "Manuel Toledano"
    },
    {
      "affs": [
        1
      ],
      "name": "Bénédicte Hivert"
    },
    {
      "affs": [
        1
      ],
      "name": "Emmanuelle Bourgeois"
    },
    {
      "affs": [
        1
      ],
      "name": "Benjamin Carpentier"
    },
    {
      "affs": [
        1
      ],
      "name": "Jean Giraud"
    },
    {
      "affs": [
        1
      ],
      "name": "Alexandre Willaume"
    },
    {
      "affs": [
        0
      ],
      "name": "François Delelis"
    },
    {
      "affs": [
        1
      ],
      "name": "Laurent Pascal"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/34h511ws6pxfh.bib",
  "cited_by": 0,
  "doi": "10.1016/j.jaccas.2026.109553",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13698917/",
  "id": "34h511ws6pxfh",
  "issns": [
    "2666-0849"
  ],
  "landing_url": "https://doi.org/10.1016/j.jaccas.2026.109553",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Cardiac Amyloidosis"
    ],
    [
      "heading",
      "Clinical Case"
    ],
    [
      "lcc",
      "RC666-701"
    ],
    [
      "openalex",
      "1312|Amyloidosis: Diagnosis, Treatment, Outcomes"
    ]
  ],
  "openalex": "W7204473942",
  "pdf_url": null,
  "pmcid": "PMC13698917",
  "pmid": "42663348",
  "published": "2026-08-27",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/34h511ws6pxfh.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:37Z",
      "native_id": "PMC13698917",
      "source": "pmc",
      "url": "https://doi.org/10.1016/j.jaccas.2026.109553"
    },
    {
      "first_seen": "2026-10-30T13:43:16Z",
      "native_id": "e02b0a13e1284d3caf230142d2eaf0a6",
      "source": "doaj",
      "url": "https://doi.org/10.1016/j.jaccas.2026.109553"
    }
  ],
  "subjects": [
    {
      "field": "biochemistry",
      "origin": "openalex:1312|Amyloidosis: Diagnosis, Treatment, Outcomes",
      "subfield": "molecular-biology"
    }
  ],
  "title": "9-Year Serial CMR Monitoring of Cardiac AL Amyloidosis Regression After Teclistamab",
  "title_text": "9-Year Serial CMR Monitoring of Cardiac AL Amyloidosis Regression After Teclistamab",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:43:16Z",
  "url": "https://research.draconitic.com/paper/34h511ws6pxfh",
  "venue": "JACC Case Reports",
  "versions": []
}